395 related articles for article (PubMed ID: 30661101)
1. Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study.
Lee KY; Park JW; Lee KY; Cho S; Kwon YH; Kim MJ; Ryoo SB; Jeong SY; Park KJ
Int J Colorectal Dis; 2019 Apr; 34(4):629-639. PubMed ID: 30661101
[TBL] [Abstract][Full Text] [Related]
2. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
3. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A
JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326
[TBL] [Abstract][Full Text] [Related]
4. Comparison between oxaliplatin therapy and capecitabine monotherapy for high-risk stage II - III elderly patients with colon cancer.
Park J; Baik H; Kang SH; Seo SH; Kim KH; Oh MK; Lee HS; Lee SH; Kim KH; An MS
Asian J Surg; 2022 Jan; 45(1):448-455. PubMed ID: 34364765
[TBL] [Abstract][Full Text] [Related]
5. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
Diao C; Cheng RC; Zhang JM; Wei XP; Su YJ; Liu QY; Xu JB
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):147-50. PubMed ID: 18646702
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
André T; Boni C; Mounedji-Boudiaf L; Navarro M; Tabernero J; Hickish T; Topham C; Zaninelli M; Clingan P; Bridgewater J; Tabah-Fisch I; de Gramont A;
N Engl J Med; 2004 Jun; 350(23):2343-51. PubMed ID: 15175436
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.
Tournigand C; André T; Bonnetain F; Chibaudel B; Lledo G; Hickish T; Tabernero J; Boni C; Bachet JB; Teixeira L; de Gramont A
J Clin Oncol; 2012 Sep; 30(27):3353-60. PubMed ID: 22915656
[TBL] [Abstract][Full Text] [Related]
8. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
Sobrero A; Lonardi S; Rosati G; Di Bartolomeo M; Ronzoni M; Pella N; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Zagonel V; Maiello E; Barni S; Rulli E; Labianca R;
J Clin Oncol; 2018 May; 36(15):1478-1485. PubMed ID: 29620994
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
11. Effect of the duration of the capecitabine regimen following colon cancer surgery in an elderly population: a retrospective cohort study.
Chen W; Dong H; Wang G; Chen J; Wang W
World J Surg Oncol; 2021 Aug; 19(1):238. PubMed ID: 34380513
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant 5-Fluorouracil/leucovorin, capecitabine, and oxaliplatin-related regimens for stage II/III colon cancer patients 66 years or older.
Jones E; Duan Z; Nguyen TT; Giordano SH; Zhao H
Cancer Med; 2023 Feb; 12(3):2389-2406. PubMed ID: 36229957
[TBL] [Abstract][Full Text] [Related]
13. A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study.
Köhne CH; Bedenne L; Carrato A; Bouché O; Popov I; Gaspà L; Valladares M; Rougier P; Gog C; Reichardt P; Wils J; Pignatti F; Biertz F
Eur J Cancer; 2013 May; 49(8):1868-75. PubMed ID: 23571150
[TBL] [Abstract][Full Text] [Related]
14. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
Ejaz A; Casadaban L; Maker AV
J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Salem ME; Yin J; Goldberg RM; Pederson LD; Wolmark N; Alberts SR; Taieb J; Marshall JL; Lonardi S; Yoshino T; Kerr RS; Yothers G; Grothey A; Andre T; De Gramont A; Shi Q
Ann Oncol; 2020 Apr; 31(4):480-486. PubMed ID: 32085892
[TBL] [Abstract][Full Text] [Related]
16. Oncologic Outcomes of Oral Adjuvant Chemotherapy Regimens in Stage III Colon Cancer: Tegafur-Uracil Plus Leucovorin Versus Capecitabine.
Tashiro J; Yamaguchi S; Ishii T; Kondo H; Hara K; Shimizu H; Takemoto K; Suzuki A
Clin Colorectal Cancer; 2017 Sep; 16(3):e141-e145. PubMed ID: 28216247
[TBL] [Abstract][Full Text] [Related]
17. Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis.
Boyne DJ; Cuthbert CA; O'Sullivan DE; Sajobi TT; Hilsden RJ; Friedenreich CM; Cheung WY; Brenner DR
JAMA Netw Open; 2019 May; 2(5):e194154. PubMed ID: 31099875
[TBL] [Abstract][Full Text] [Related]
18. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
André T; Boni C; Navarro M; Tabernero J; Hickish T; Topham C; Bonetti A; Clingan P; Bridgewater J; Rivera F; de Gramont A
J Clin Oncol; 2009 Jul; 27(19):3109-16. PubMed ID: 19451431
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.
Twelves C; Scheithauer W; McKendrick J; Seitz JF; Van Hazel G; Wong A; Díaz-Rubio E; Gilberg F; Cassidy J
Ann Oncol; 2012 May; 23(5):1190-1197. PubMed ID: 21896539
[TBL] [Abstract][Full Text] [Related]
20. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.
Souglakos J; Boukovinas I; Kakolyris S; Xynogalos S; Ziras N; Athanasiadis A; Androulakis N; Christopoulou A; Vaslamatzis M; Ardavanis A; Emmanouilides C; Bompolaki I; Kourousis C; Makrantonakis P; Christofyllakis C; Athanasiadis E; Kentepozidis N; Karampeazis A; Katopodi U; Anagnosopoulos A; Papadopoulos G; Prinarakis E; Kalisperi A; Mavroudis D; Georgoulias V
Ann Oncol; 2019 Aug; 30(8):1304-1310. PubMed ID: 31228203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
